Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B

• Published in: Zhonghua gan zang bing za zhi Vol. 20; no. 12; p. 888
• Main Authors: Jiang, Hong-xiu, Han, Guo-rong, Wang, Cui-min, Ji, Ying
• Format: Journal Article
• Language: Chinese
• Published: China 01.12.2012
• Subjects: Adult; Antiviral Agents - therapeutic use; DNA, Viral - blood; Female; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - transmission; Humans; Infant; Infectious Disease Transmission, Vertical - prevention & control; Lamivudine - therapeutic use; Mothers; Pregnancy; Pregnancy Complications, Infectious - drug therapy; Pregnancy Complications, Infectious - virology; Pregnancy Outcome; Pregnancy Trimester, Third; Treatment Outcome; Young Adult
• ISSN: 1007-3418
• DOI: 10.3760/cma.j.issn.1007-3418.2012.12.003

To evaluate the therapeutic efficacy and safety of lamivudine treatment in late pregnancy by analyzing the maternal-fetal outcomes of chronic hepatitis B (CHB) mothers featuring hepatitis B e antigen (HBeAg)-positivity and highly viremic status. A total of 256 pregnant women in the second or third trimester with monoinfected CHB, HBeAg-positivity, and HBV DNA more than 6 log10 copies/mL were divided into two groups: lamivudine (lam) treatment (n=164) or no treatment (controls; n=92). All infants were treated with hepatitis B immune globin (HBIg; 200 IU) within 12 hrs of birth and 15 days later, and were given the recombinant HBV vaccine (20 mug) at 0, 1 and 6 months. All infants were followed-up to at least seven months and hepatitis B surface antigen (HBsAg) and HBV DNA levels were used to determine perinatal transmission (PT) rates. The mothers' data from routine blood analysis, tests of hepatic and renal function, detection of HBV markers and HBV DNA were retrospectively analyzed to determine changes assoc